Mutation, selection, and evolution of the Crohn disease susceptibility gene CARD15

Kathy King1, Mohammed F Sheikh, Andrew P Cuthbert

  • 1Department of Medical and Molecular Genetics, Guy's, King's and St. Thomas' School of Medicine, King's College London, London, United Kingdom.

Human Mutation
|November 10, 2005
PubMed

Insights

This study investigated CARD15 (NOD2) gene mutations in Crohn disease (CD). Most CD patients heterozygous for common mutations are true heterozygotes, supporting a gene dosage model for CD susceptibility.

Area of Science:

  • Genetics
  • Molecular Biology
  • Gastroenterology

Background:

  • Three common CARD15 (NOD2) gene mutations are linked to Crohn disease (CD) susceptibility, suggesting a gene dosage model.
  • The existence of rare CARD15 variants raises questions about recessive models for CD in heterozygotes carrying common mutations.

Purpose of the Study:

  • To investigate whether heterozygotes for common CARD15 mutations also carry rare pathogenic variants, which would impact CD genetic models.
  • To develop and apply a strategy for evaluating potential CARD15 disease susceptibility alleles (DSAs).

Main Methods:

  • Screened CARD15 for mutations in 100 CD patients heterozygous for common mutations.
  • Assessed evolutionary conservation of CARD15 residues by sequencing orthologs in primates and other species.
  • Evaluated predicted protein structure/function effects and genotyped potential DSAs in cases and controls.

Main Results:

  • 11 out of 100 CD patients had a second potential pathogenic CARD15 mutation.
  • Identified four novel nonsynonymous mutations, including one causing premature termination (c.2686C>T, p.Arg896X).
  • Two potential DSAs (c.2107C>T, p.Arg703Cys and g.2238T>A, c.74-7T>A) were significantly associated with CD.

Conclusions:

  • The findings support a gene dosage model for CD susceptibility, as most carriers of common CARD15 DSAs appear to be true heterozygotes.
  • The study identified novel CARD15 mutations and potential DSAs associated with CD.
  • A generalizable strategy for assessing mutation pathogenicity and genetic models in complex disorders was developed.

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Exon Recombination02:32

Exon Recombination

The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Evolution of New Traits in Microbes01:24

Evolution of New Traits in Microbes

Microorganisms evolve rapidly due to their large population sizes and short generation times, often exhibiting measurable changes within days under laboratory conditions. Natural selection acts on standing genetic variation, enabling the retention and amplification of beneficial traits that confer fitness advantages in changing environments.Adaptive Pigment Regulation in RhodobacterIn Rhodobacter, a genus of purple non-sulfur bacteria, light-harvesting pigments such as bacteriochlorophyll and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...